Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GJB2 | P29033 | 2/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.51 |
| ▸ | TACR2 | P21452 | 3/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | NT5E | P21589 | 1/20 | 0.47 |
| ▸ | GJA1 | P17302 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.44 |
| ▸ | CDC25B | P30305 | 3/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10408745 | 0.93 | HTR1A (0.53) | GJB2PDE4DSLC6A2TACR2HTR1A | |
| SCHEMBL10408744 | 0.93 | HTR1A (0.53) | GJB2PDE4DSLC6A2TACR2HTR1A | |
| SCHEMBL8723384 | 0.91 | HTR1A (0.52) | PDE4DSLC6A2TACR2HTR1ANT5E | |
| SCHEMBL21657199 | 0.91 | HTR1A (0.52) | PDE4DSLC6A2TACR2HTR1ANT5E | |
| SCHEMBL28943950 | 0.91 | HTR1A (0.52) | PDE4DSLC6A2TACR2HTR1ANT5E | |
| SCHEMBL21013403 | 0.90 | SLC6A2 (0.53) | GJB2PDE4DSLC6A2TACR2HTR1A | |
| SCHEMBL13430417 | 0.90 | GJB2 (0.52) | GJB2PDE4DSLC6A2TACR2HTR1A | |
| SCHEMBL5473070 | 0.90 | GJB2 (0.52) | GJB2PDE4DSLC6A2TACR2HTR1A | |
| SCHEMBL10778287 | 0.90 | GJB2 (0.52) | GJB2PDE4DSLC6A2TACR2HTR1A | |
| SCHEMBL13430414 | 0.90 | GJB2 (0.52) | GJB2PDE4DSLC6A2TACR2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230045939-A1 | STABLE VACCINE AGAINST CLOSTRIDIUM DIFFICILE | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230045939-A1 | STABLE VACCINE AGAINST CLOSTRIDIUM DIFFICILE | DDOST, SI, CD4 | GJB2 2102/4885PDE4D 3352/4885SLC6A2 4157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.